Blood Screening Market Size, Share, Report, Analysis (2018 - 2023)

Global Blood Screening Market was valued at USD 2.35 Billion in the year 2017. Global Blood Screening Market is further estimated to grow at a CAGR of 4.46% from 2018 to 2023. North America region holds the highest market share in 2017 with APAC region is considered as the fastest growing market in the forecasted period. At a country level, the U.S is the biggest market in 2017 and it is projected to grow at a gradual pace in the coming years.

Get Free Access to Sample Report @ https://genesismarketinsights.com/Sample_Request/GENRE074

Grifols (Spain), Roche Diagnostics (Switzerland), bioMérieux (France), Abbott Laboratories (U.S.) are some of the key manufacturers in the Global Blood Screening Market with Roche Diagnostics holding the substantial market share because of its better global presence both at production and at an operational level. Rising research and development expenses to cater changing demand of end users, similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of Tier 1 and Tier 2 manufacturers in recent years.

Drivers
Boosting Demand for blood supply
Increased focus on the safety of blood

Restrain
Lack of regulatory standards
Level of required financial investment & lack of technical expertise

Opportunity
Rising importance of diagnostics in improving healthcare quality
Development of emerging markets for NAT technology.

Challenge
Supply of safe blood
Intense competition and reduced healthcare reimbursement

The NAT (Nucleic Acid Test) segment is likely to hold the top market share during the forecast period. The growth can be attributed to the increasing number of blood donations, rising incidence of infectious diseases, and increasing capacity (disposable income) to pay for NAT-tested blood.

On the other hand, hospitals & clinical Laboratories for users is expected to grow at the highest CAGR of during the year 2017-2023. Majorly because there is increasing demand for donated blood, growing number of organ transplantation surgeries, rising awareness regarding the safety of blood, increasing number of donations worldwide, and growth in government funding to charitable trusts.

Key Benefits for Stakeholders

• Blood screening Manufacturers, Distributors, and Retailers
• Research and Consulting organization
• Technology Standards Organizations, Forums, Alliances and Associations
• End-use industries
• Regulatory bodies, policy actors, and consumers.

By Products & Services

• Instruments
• Software and Services
• Reagents & Kits
• Assays/consumables

By Technology

• Western Blot Assay
• Reverse Polymerase Chain Reaction (RPCR)
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Nucleic Acid Test (NAT)
• Next-Generation Sequencing (NGS)
• Rapid Tests

By Users

• Hospitals
• Blood Banks

By Region

• North America
• Europe
• Asia-Pacific
• RoW

Key Market Players

• Abbott Laboratories
• Ortho Clinical Diagnostics, Inc.
• Biomérieux SA
• Grifols SA
• F. Hoffmann-La Roche AG
• Becton, Dickinson, and Company
• Qiagen Netherlands (includes Digene)
• Bio-Rad Laboratories, Inc.
• Agilent Technologies (Dako)
• Trinity Biotech

Read Report Overview with Full TOC @ https://genesismarketinsights.com/viewreport/75/28/Blood-Screening-Market

About Us:

Genesis Market Insights (GMI), is a subsidiary of Genesis Management & Market Research Pvt.Ltd. (GMMR) having a strong experience both in primary and secondary market research serving small to large scale enterprises across globe.

Contact Us;

Genesis Market Insights (GMI)
902 Broadway, 6th Floor,
New York, NY 10010
(212) 634-4560

This release was published on openPR.